Difference between revisions of "Research budget in pharmaceutical industry"
Jump to navigation
Jump to search
Peter Friedl (talk | contribs) |
Peter Friedl (talk | contribs) |
||
(5 intermediate revisions by the same user not shown) | |||
Line 2: | Line 2: | ||
==Description:== | ==Description:== | ||
In the pharmaceutical industry research and development is a very time-consuming and demanding task. Only a few new drugs make it through development, testing and product approval each year. This asks for a large R&D budget over several years for pharmaceutical companies. Even then a success, the development of a new, good selling drug, is of course not guaranteed. | |||
==Enablers:== | ==Enablers:== | ||
* Size of the pharmaceutical company | |||
* Revenue streams of the company | |||
* Marketability of pharmaceuticals | |||
* Intellectual Property rights for pharmaceuticals (link to driving force [[IP rights]]) | |||
* Funding of R&D projects by the health system | |||
* General prosperity | |||
==Inhibitors:== | ==Inhibitors:== | ||
* Unstable and unpredictable general economic conditions | |||
* Facilitating of the production of generica | |||
==Paradigms:== | ==Paradigms:== | ||
R&D in pharmaceutical industry is a very time and money consuming undertaking that requires predictable future revenue streams to be viable for the respective companies | |||
==Experts:== | ==Experts:== | ||
<br> | |||
==Timing:== | ==Timing:== | ||
<br> | |||
==Web Resources:== | ==Web Resources:== | ||
* [1] [http://www.globalissues.org/article/52/pharmaceutical-corporations-and-medical-research Pharmaceutical Corporations and Medical Research] - article on Global Issues | * [1] [http://www.globalissues.org/article/52/pharmaceutical-corporations-and-medical-research Pharmaceutical Corporations and Medical Research] - article on Global Issues | ||
* [2] [http://www.cbo.gov/ftpdocs/76xx/doc7615/10-02-DrugR-D.pdf R&D in the Pharmaceutical Industry] - a Congressional Budget Office Study |
Latest revision as of 14:49, 18 September 2009
This page is under construction and edited by Peter Friedl EMBA09. In case of any questions/remarks, feel free to contact me
Description:
In the pharmaceutical industry research and development is a very time-consuming and demanding task. Only a few new drugs make it through development, testing and product approval each year. This asks for a large R&D budget over several years for pharmaceutical companies. Even then a success, the development of a new, good selling drug, is of course not guaranteed.
Enablers:
- Size of the pharmaceutical company
- Revenue streams of the company
- Marketability of pharmaceuticals
- Intellectual Property rights for pharmaceuticals (link to driving force IP rights)
- Funding of R&D projects by the health system
- General prosperity
Inhibitors:
- Unstable and unpredictable general economic conditions
- Facilitating of the production of generica
Paradigms:
R&D in pharmaceutical industry is a very time and money consuming undertaking that requires predictable future revenue streams to be viable for the respective companies
Experts:
Timing:
Web Resources:
- [1] Pharmaceutical Corporations and Medical Research - article on Global Issues
- [2] R&D in the Pharmaceutical Industry - a Congressional Budget Office Study